



Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

Abandonment, 281

Abbreviated Injury Scale, 422

Absorptiometry, dual energy x-ray, 612–613
dual-photon, 612–613

Abuse, cycle of violence and, 360–361
definition of, by different cultural
groups, 360

financial. See *Financial exploitation*.
of elderly. See *Elder abuse*.

Abusers, criminal liability of, 394–395
domineering, 284

impaired, 284

narcissistic, 284

overwhelmed, 284

recognizing and understanding of,
283–284

sadistic, 284

types of, 284

Acetaminophen, in arthritis pain, 557
in osteoarthritis, rheumatoid arthritis, and
juvenile chronic arthritis, 552–553

Acupuncture, in osteoarthritis, 597

Adult protective services, as community
approach to elder abuse, 431–435
case substantiation by, 433

definitions of, 451

developments in, 452–453

history of, 431–432, 450

interventions by, 433–434

investigations by, 432

myths and misperceptions about,
434–435

need for multidisciplinary
collaborations, 435

patchwork of services throughout
country, 451

state, 389–392

Advance directives, and designated proxy
decision maker, 201
as planning tools, 241–242

effectiveness of, 196–197

history of, 194–196

limitations of, 202, 203

proxy decision makers and, 230–231

proxy decisions and, 197–198

proxy interests and, 198

recommendations concerning, 204–205

stability of decisions in, 198–201

tempered interpretation of, 202

use of, evolution of, 201–202

prevalence of, 196

review of literature on, 196–201

written, when not enough, 193–209

Aerobic exercise, selection of, 751

African Americans, end-of-life care and,
239–253

false assumptions of end-of-life care
and, 239

palliative care and, case illustrating,
248–250

synthetic approach to palliative care and,
245–246

Age, impact on body mass index, 689
treatment for obesity and, 694–695

Agonist-antagonist, opioid, mixed, 478–479

Airway obstruction, pathophysiology of,
702–704

Allopurinol, 502, 585

Alzheimer's dementia, 261

Alzheimer's disease, as risk factor for
abuse, 288

nursing home placement in, 289

prognosis in, 316

stages of, 316

American Pain Society, 94

Amitriptyline, 480

Amphetamines, for treatment of obesity, 736

Anakinra, 519

Analgesics, nonopioid, 472–474
topical, 483

Androgens, osteoporosis and, 619

Anticonvulsants, 482
opioids and, 104

Antidepressants, 479–480
tricyclic, opioids and, 104–105

Anti-infective agents, opioids and, 103

Antimalarials, clinical pharmacology of, 661
efficacy of, 661
history of, 660
mechanism of action of, 660–661
toxicity of, 661–662

Antirheumatic drugs, disease-modifying, 516,
517–518, 554
use in rheumatoid arthritis, 649–669

Anxiolytic agents, 481–482

Area Agencies on Aging, 444

Arteritis, giant cell, 632–633

Arthralgia, drug-induced, 585–586

Arthritis, crystal-associated, in elderly,
491–511
rheumatoid. See *Rheumatoid arthritis*.

Arthroplasty(ies), total joint, comorbid conditions influencing, 533–534
in osteoarthritis, 527–528
knee range following, 529
mortality following, risk factors for, 528
nonsurgical medical factors influencing, 533–534
obesity and, 534
outcomes of, health-related quality of life following, 529–530
determinants of, 531–535
pain and function following, determinants of, 528–529
to evaluate, 528
passive motion machine use following, 529
patient outcomes after, 527–541
patient satisfaction with, 530–531
perioperative surgical complications influencing, 531–532
prosthesis-related factors influencing, 532
psychologic factors influencing, 534–535

Aspirin, 472–473

Assessment instruments, **121–146**
broad screening and unfolding approaches in, 123–124

care and services questions in, 136–138
comprehensive, challenges of, 123
domains for, 124, 125
for assessment of competency and communication, 126–128
for assessment of physical function, 128–132
for assessment of psychological function, 132
for assessment of subjective experience in, 138–141
for in-depth/research assessment by domain, 124–139
physical examination and test, 122
question-based, purposes of, 122–123
screening questions as, 121
social and environmental questions in, 132–135
spiritual questions in, 135–136

Azathioprine, 517

B

Baclofen, 482

Balance exercises, 753

Bariatric beds, 771–772

Bariatric mattresses, 772

Bariatric procedures, in obesity, 697, 706
postoperative complications of, 781

Bariatric programs, in nursing homes,
769–794
admissions and discharge protocols for, 773–774
bathing in, 775
care in, 774
development of, 770
environmental modifications for, 771
equipment for, 771–773
financial implications of, 770–771
for short-term rehabilitation, 774,
783–784
maintenance of dignity and privacy in, 784
medical care in, 780
medical considerations in, 780–781
medications management in, 782
mental health care in, 782
nursing care in, 774–775
nutritional care planning and interventions in, 779–780
nutritional evaluation in, 776–779
physical activity and exercise in, 782–783

processes and outcomes in, monitoring of, 785, 786 quality of care in, 785–786 rehabilitation in, goal of, 783 skin care in, 775 staff safety in, 785 staff training for, 785 transfer and mobility problems in, 772, 773, 783–784 transportation requirements for, 784

B
Bariatrics, 760
Beds, bariatric, 771–772
Behavioral clusters, elder abuse and, 337
Behavioral therapy, in obesity, 720
Benzodiazepines, opioids and, 104
Bisphosphonates, osteoporosis and, 617–618
Body composition, and function, in obese elderly, 682 studies of, and mobility disability, 681 functional limitations and, 681

Body mass index (BMI), as indicator of obesity, 747 elevated, physical performance testing in, 680–681 high, calculation of, 776 functional limitations in, 678–679 mobility disability in, 678

Bone, cells of, and proteins in, 603–604 hormonal regulation of, 604 composition of, 603 remodeling process in, 605 resorption and formation of, 603 turnover of, methods to approximate, 610

Bone mass, factors affecting, 606–607

Breathing, sleep-disordered, 702 events during, 703

Bruises, as sign of physical abuse, 342

Buprenorphine, 479

Butorphanol, 479

C
Calcitonin, bone cells and, 604, 606, 617 osteoporosis and, 617

Calcitriol, osteoporosis and, 616

Calcium, osteoporosis and, 616

Calcium phosphate (bcp)-hydroxyapatite deposition disease, basic, 506–507

Calcium pyrophosphate dihydrate crystals, 491

Calcium pyrophosphate dihydrate deposition disease, 491, 502–506, 520–521 chondrocalcinosis in, 503, 505 clinical features of, 504 diagnosis and differential diagnosis of, 504–506 management of, 506 metabolic basis of, 503

Calorie restriction, and protein liquids, for weight loss, 730

Canadian Institute of Health Care Research, Palliative Care Research Initiative of, 263

Cancer patient(s), cognitive impairment in, 96 delirium in, 110–115 palliation of symptoms in, 96 steps in expression of pain in, 95

Candidiasis, 775 prevention of, 763 risk of, in diabetes mellitus, 762–763

Capsaicin, 483

Cardiovascular diseases, obstructive sleep apnea and, 708–709

Cardiovascular risk factors, in obesity, 693

Caregiver(s), burden faced by, 78–79 burden of, Zarit Burden Interview to assess, 327, 328 depression in, 319, 320 ergonomics and, 765 family, characteristics of, elder abuse and, 341 injury of, economic and noneconomic costs of, 761 lift teams for prevention of, 765

Caregiver stress theory, 283

Cataracts, glucocorticoids and, 641

Centrally acting agents, 474–478

Cholesterol, orlistat and, 742–743

Cholinesterase inhibitors, in Alzheimer's disease, 317

Chondrocalcinosis, in calcium pyrophosphate dihydrate deposition disease, 503, 505

Churg-Strauss syndrome, 637

Civil liability, elder abuse and, 394 of abusers, 394

Clearinghouse for Abuse and Neglect of the Elderly (CANE), 444

Clonazepam, 481–482

Clonidine, 483

Cockcroft-Gault formula, 471

Code enforcement teams, 441

Codeine, 475

Cognitive decline, dementia and, 339

Cognitive function, obstructive sleep apnea and, 710

Cognitive impairment, pain in, assessment of, 574
behavioral manifestations of, 573
symptom assessment in, 96–99

Colchicine, 499, 500, 585, 596–597

Community, approaches to elder abuse in. See *Elder abuse, community approaches to*.

Comprehensive Sexual Assault Assessment Tool (CSAAT), 402–403, 415–425
revised (CSAAT-E), 420–421, 422, 424

Computed tomography, quantitative, 612–613

Consumer fraud, 368

Continuous positive airway pressure therapy, beneficial effects of, 709
in sleep apnea, 706, 708, 710

Coronary artery disease, and sleep apnea, mortality in, 708–709

Corticosteroids, in gout, 500

Cost-benefit research, and palliative care, 149–150
gold standard for, 148–149
health care resources and, 148
non-health care resources and, 148
on health care interventions, 147–148
quality and quantity of life and, 148–149

Counseling, for healthy obese patients, 750

COX I/COX II agents, 473–474, 595

Creatine kinase, testing of, in statin-associated myopathy, 580

Credit cards, protection of, 376, 377

Criminal liability, elder abuse and, 393–394
of abusers, 394–395

Cryoglobulinemic vasculitis, 639

Crystal-associated arthritis, 491–511

Cultural groups, definitions of abuse by, 360

Cultural issues, and elder care, case illustrating, 357–358
family members return home and, 358–359
and elder mistreatment, 355–364

Cycle of violence, 360–361

Cyclobenzaprine, 482–483

Cyclo-oxygenase-2 (COX-2) specific inhibitors (COXIBs), 517

Cyclosporin, 517

Cytokine therapies, clinical pharmacology of, 662–663
efficacy of, 663
history of, 662
mechanism of action of, 662
toxicity of, 663–664

Cytotoxic therapies, in vasculitis, 642

D

Deaf community, access to care, 362

Death, physician action and, 211–212
top 10 causes of (1900 and 2000), 76

Decision-making, medical, acceptable to family and health care team, 220
wants/goals of patients and, 215–217

Decision-making capacity, loss of, deciding for patients in, 228–231

Dehydration, as sign of neglect, 344

Delirium, agitated, pain assessment in, 96–97
assessment by third party in, 97
assessment of patients with, 97–98
causes of, 99
terminal, pain and, research on, in elderly, 93–119

Dementia, and cognitive decline, 339
and depression, 286
assistance required in, 319
care in, at home, 318–322
in nursing homes, 322–324
elder abuse in, 315–332
diagnosis of, 325–326
treatment, intervention, and prevention of, 326–329
etiologies of, 315
Folstein MMSE in assessment of, 98
medications in, 317
progression of, losses in, 315–316
therapies for, 316

Densitometry, single-photon, 612

Depression, dementia and, 286
weight loss and, 721

Diabetes mellitus, glucocorticoids and, 641
in obesity, 780

Dicloferac, 597

Dietary management, in obesity, emphasis of, 727
of obesity, 697
in elderly, 725–733

Dietary restriction, and walking, for weight loss, 730

Diet(s), healthy, for older adults, 730
for weight-loss program, 717–718

low-carbohydrate, 730

poor, and inactivity, deaths caused by, 761

Diogenes syndrome, 343–344

Diuretics, and gout, 497

Domestic violence legislation, state, 389–392

Drug absorption, in elderly, 650–651

Drug distribution, in elderly, 651

Drug elimination, in elderly, 651–652

Drug-induced lupus. See *Lupus, drug-induced*.

Drug metabolism, in elderly, 651

Drug-related adverse events, 577

Drug-related errors, morbidity and mortality related to, 577

Drug therapy, in obesity, 727

Drugs, analgesic, interaction of, 102–103
causing arthralgias, 585
dosage of, factors affecting, 466–467
management of, in bariatric programs in nursing homes, 782
promoting weight gain, and alternatives, 692
weight-loss, in elderly, trials of, 744

Durable Power of Attorney for Health Care (DPAHC), 195

E

Education, in geriatrics and palliative medicine, 11–12
in palliative care, 165–175

Elder abuse, and neglect, 279–292
and exploitation, policy issues on, 449–457
clues for suspecting, 341–345
in long-term care, 333–354
in nursing homes, 323–324
intervention in, 347–349
legal definitions of, 385–386
legal response to, 386–393
medical implications of, 293–313
patient characteristics and, 339–340
prevention of, 346–347
reporting of, barriers to, 345–346
risk factors for, 338–341

scope of problem of, 337–338
staff risk factors and, 340–341

as complex issue, 451–452

as criminal offense, 363

as offense, 360

background of, 279–280

behavioral clusters and, 337

by family and “friends,” 383–384

characteristics of abuser and, 450

commission or omission in, 336

community approaches to, 429–447
adult protective services and, 431–435
case illustrating, 442–443
code enforcement teams in, 441
duty to report in, 430–431
fatality review teams in, 441
interdisciplinary team in, 430, 442–443
medical case management teams in, 435–438, 442–443
victim advocacy organizations, 441–442

context of care and, 336

definition(s) of, 280–281, 334–337, 355
based on interviews of nurses in nursing homes, 335–336

dementia and, 315–332

diagnosis of, in dementia patients, 325–326

domestic, legal and governmental responses to, 383–398
response of federal government to, 387–388
response of state governments to, 388–393

facility characteristics and, 341

failure to report, legal actions in, 393–394

family caregiver characteristics and, 341

forms of, 335, 356

health care professionals and, 302–303
barriers to reporting by, 304–306

health care system use and, 298–299

health care team and, future implications for, 289

identification of, 285–286

ignored, reasons for, 450

in dementia patients, treatment of, 326–329
intervention, and prevention of, 326–329

in home, 319–320

in inability to communicate, 320

in special populations, 286–289

inattention to, 327

incidence of, 285, 317, 321

intentional or unintentional act and, 336–337

intervention in, as controversial, 329

mortality and, 301–302

nursing home placement and, 299–301
 occurrence of, 281–282
 perception of hurt and, 336
 perpetrators of, legal actions against, 394–395
 physical indicators of, 287
 prevalence of, 384–385
 preventive approach to, 327
 quality of life, fear and social isolation and, 296–297
 functional decline and dependency and, 294
 self-rated health and helplessness and, 295–296
 stress and psychologic decline and, 297–298
 reporters of, 285
 reporting of, fear of, 361
 physicians, 294
 risk factors for, 281–282, 338–341
 in long-term care, 323
 screening questions, 286
 strategies and interventions in, 306–308
 theories to explain, 318
 types of, 322

Elder Justice Act (Senate Bill 333), 454–456

Elder Law attorney, 370–371, 376

Elderly, in United States, as fastest growing segment of population, 279, 385
 obese. See *Obesity*.
 pain in, treatment of, 93–94
 palliative care and, 49
 pharmacodynamics in, 650
 pharmacokinetics in, 650
 pharmacologic agents and, 743–744
 physiologic changes in, 650–652
 sexual abuse of, studies of. See *Sexual abuse, of older adults*.
 sleep apnea in, 701–712
 sleep in, 707–708
 “unbefriended,” 362–363
 weight gain as common in, 748
 weight loss and maintenance in, physician-assisted, 713–723

Elderly female, sexual abuse of, forensic markers in, 399–412

Emotional abuse, 281

End of life, consensus on, 226–227
 ethics committees and, 235
 limitation of treatment at, 223–238
 needs at, screening tool, 140–141
 role of law and legal precedent in, 224–225
 types of treatments for, 227–228
 withdrawing and withholding, as ethically/legally equivalent, 225

End-of-life care. See also *Palliative care*.
 African Americans and, 239–253
 agenda for policy improvement, 255–272
 assumptions about, 240
 coordination of services for, 263
 doctor/patient communication and, 243
 in chronic illness with exacerbations and sudden death, 260–261
 in long dwindling, 261
 in modern era, 1
 in short period of terminal decline, 259
 Medicare and, 262
 methods to achieve reform of, 263–266
 near-term opportunities for reform of, 266
 needs in, systems to support, 262–263
 opioids in, ethical and legal issues in use of, 232–233
 physician training in communication for, 265
 policy changes for reform of, 266
 qualifying for, on basis of need, 258–259
 quality care at, questions to shape research on, 264–265
 research for reform of, 266

End-of-Life/Palliative Education Resource Center (EPCR), 172

Energy expenditure, in weight-loss program, 753–754

Energy requirements, calculation of, in obesity, 778

Equipment, and furniture for obese patients, 764
 exercise, 752
 for bariatric programs in nursing homes, 771–773
 specialized, to facilitate physical activity, 751

Ergonomics, caregivers and, 765

Estrogen replacement, osteoporosis and, 616–617

Etanercept, 519

European Organization for Research and Treatment of Cancer (EORTC), 138–139

Euthanasia, abuse of, 181
 active, 180
 passive, 179
 physician-assisted suicide and, 233–234

Evidence-based medicine, definition of, 261 in palliative care, 261

Exercise, and physical activity, in bariatric programs in nursing homes, 782–783
 role in weight management and functional improvement, 747–757

in weight control, 749
in weight-loss program, 718, 731
types of, for seniors, 751–753

Exercise equipment, 752

Exercise programming, for seniors, 749–751

Exploitation, elder abuse, and neglect, policy issues on, 449–457
financial. See *Financial exploitation*.

Extended care facilities. See *Nursing home(s)*.

F

Fatality review teams, 441

Fear, and social isolation, quality of life and, 296–297

Fentanyl, 478
metabolism of, 102–103
routes of administration of, 101–102

Fiber intake, for older adults, 728

Financial exploitation, 281, 365–382
as form of abuse, 359
cases illustrating, 365–366
cognitive impairment as risk factor for, 320
definition of, 367
detection and screening protocol for, 372–373
documentation of, 373–374
evidence of, 368
federal laws concerning, 378–379
follow-up in, 375–380
identification of, 367–369
Internet resources on, 380–381
legal aspects of, 369–372
legal definition of, 386
medical aspects of, 371–372
of older Americans, 395–396
persons perpetrating, 367
prevention of recurrence of, 378
prosecution of, 369, 370
recognition of, difficulty in, 366–367
removal of elder from situation of, 375–380
reporting of, 374–375
state laws concerning, 379–380

Fitness Arthritis and Seniors Trial (FAST), 683

Flexibility exercises, 753

Fluid and nutrition, orally ingested, voluntary refusal of, 231–232

Fluid intake, for older adults, 728

Folstein MMSE, in assessment of dementia, 98

Forensic markers, of sexual abuse of elderly female, 399–412

Fractures, as sign of physical abuse, 342

Fright mail, 395

Functional Assessment of Chronic Illness Therapy (FACIT), 139

Functional decline, and dependency, quality of life and, 295–296
in relation to body mass index, 680
obesity and, 677–687
weight loss/weight gain as risk factor for, 679

Functional impairment, homebound status and, 680

Functional limitations, obesity-associated, 682
studies of body composition and, 681

Futile treatment, 211
demands for, “good death” and, 219–220
prevention of requests for, 217–219

Futility, definition(s) of, 213–215
in evolution, 211–222
patient-centered, 214–215
and goals of care, 216–217
physiologic, 213
professional integrity-centered, 213
quantitative, 213–214
resource-centered, 214
social consensus, 215
without goals of care, 217

G

Gastric bypass surgery, care following, 781

Gastroesophageal reflux, sleep apnea and, 709–710

Gay community, violence toward, and exploitation of, 362

Geriatrics, and palliative medicine, 57–65.
See also *Palliative care, geriatric medicine and*
challenges and lessons in, 12–14
clinical practice of, 9–10
comparison between, 8
conceptual framework of, 4
education in, 11–12
historical comparisons of, 7–8
history of, 4
knowledge and research in, 8–9
timelines in, 5–6

Giant cell arteritis, 632–633

Glucocorticoids, and cataracts, 641
 and diabetes, 641
 and hypertension, 641
 and myopathy, 641–642
 and osteoporosis, 607–608, 641
 and vasculitis, 641

Glucosamine/chondroitin, 595–596

Gout, 491, 492, 521
 acute, management of, 499–500
 clinical features of, 493–494
 diagnosis and differential diagnosis of, 497–498
 diuretic use and, 497
 elderly-onset, clinical features of, 494
 epidemiology and pathogenesis of, 492–493
 female frequency of, 495
 incidence of, 584
 intercritical, 500–501
 management of, 498, 499
 polyarticular, 494–495
 prevalence of, 492
 serum uric acid and, 584
 small-joint finger involvement in, 495–496
 tophaceous, early atypical, 496–497

Health Utilities Index, 151–152

Henoch-Schönlein purpura, 638

Histamine H₂-antagonists, opioids and, 104

Home environment, modification of, in obesity, 764

Hospice care, 76
 costs and benefits of, 147
 Medicare and, 75, 77
 prognostic requirements of, 77

5-HT selective reuptake inhibitors, 479–480

Hyaluronic acid, 596

Hydrocodone, 475

Hydromorphone, 478

Hygiene, poor, signs of, 343–344

Hypertension, glucocorticoids and, 641
 obstructive sleep apnea and, 708
 sibutramine and, 737

Hyperuricemia, chronic, therapy of, 501–502
 epidemiology and pathogenesis of, 492

Hypothyroidism, in obesity, 692

H

Health, and helplessness, self-rated, quality of life and, 295–296

Health care, at end of life, futile, discontinuation of treatment in, 242
 unwanted and unnecessary, 241
 costs of, insurers and, 212
 spiraling and patient/family expectations, 212–213
 goals of, futility without, 217
 patient-centered futility and, 216–217

Health care facilities, policy changes in, for morbid obesity, 765–766

Health care interventions, cost-benefit research on, 147–148

Health care professionals, elder abuse and, 302–306

Health care system, use of, elder abuse and, 298–299

Health care team, and elder abuse, future implications for, 289
 and family, medical decision-making and, 220

Health Information Portability Accountability Act (HIPAA), 432

I

Illness(es), chronic, in United States, 76
 Medicare and, 76–77
 worsening and causing death, 76
 patient/family experience of, 18–20
 patterns of, changing, 18
 trajectories of, and organization of care, 259–262
 frequency of, 261–262

Immobility, skin injury related to, 761–762

Incontinence, in nursing homes, 781

Infection, and vasculitis, 640–641

Intertrigo, 775

J

Jenny Craig, 719

Joint laxity, osteoarthritis and, 592

K

Kevorkian, Jack, 179

Knee, total arthroplasty of, complications following, in obesity, 784

L

LA Weight Loss Centers, 719

Laboratory evaluation, in obesity, 693–694

Leflunomide, clinical pharmacology of, 659
efficacy of, 659–660
history of, 658
mechanism of action of, 658–659
toxicity of, 660

Legal guardianship, 434

Legal intervention teams, 438–441
civil justice system and, 440
criminal justice system and, 439
criminal prosecution teams and,
439–440
fiduciary abuse specialist teams,
440–441

Lidocaine, 483

Life, quality of, preferred over quantity of life,
240–241

Life-sustaining treatment, termination of,
definition of, 180–181

Lifestyle change, psychological and
educational approaches to, 729

Lift teams, for prevention of caregiver injury,
765

Lifts, for bariatric unit, 772

Long-term care, sites of, 333

Long-term care facilities, care of obese patients
in, 761
elder abuse and, 287–288, 323,
333–354

Lupus, drug-induced, clinical manifestations
of, 582–583
definition of, 582
diagnostic tests in, 583
medications associated with, 583
treatment of, 584

M

Macrolides, clearance of opioids and, 103

Mail fraud, 395

Malnutrition, symptoms of, 725

Mandibular advancement devices, in sleep
apnea, 706

Mattresses, bariatric, 772

McGill Quality of Life Questionnaire - revised
(MQOL), 139

Medicaid, coverage provided by, 262

Medical assessment, in obese older patients,
689–699

Medical case management teams, 435–438
common diagnoses of, 437–438
history of, 436
house calls by, 437
interventions by, 438
work of, 436–438

Medical neglect, signs of, 343

Medical Outcomes Study, Short Form Health
Survey, 139

Medicare, chronic illness and, 76–77
end-of-life care and, 262
hospice care and, 75, 77

MediCaring, 266–268
basic tenets of, 268

Medications. *See Drugs and
specific medications.*

Medicine, twin efforts to transform, history and
lessons learned from, 3–15

Mental health care, in bariatric programs in
nursing homes, 782–783

Meperidine, 476–477

Methadone, 477
action of, 109
for cancer-related pain, 108
in palliative care, advantages of, 109
metabolism of, 103
rotation with morphine, 109–110

Methotrexate, 517, 633, 642, 652–655
clinical pharmacology of, 653–654
efficacy of, 654–655
history of, 652
mechanism of action of, 652, 653
side effects of, 655

Metoclopramide, opioids and, 105

Milwaukee shoulder-knee syndrome, 507

Mirtazapine, 481

Mistreatment of elders. *See Elder abuse.*

Mobility disability, studies of body
composition and, 681

Monoamine oxidase inhibitors, opioids
and, 105
sibutramine and, 737

Monosodium urate crystals, 491

Morphine, 475–476
intraspinal use of, 102

Myopathy(ies), glucocorticoids and, 641–642
related to statins, 578–581

N

National Center of Elder Abuse (NCEA), 280, 285, 366, 387, 444

National Clearinghouse on Abuse in Late Life, 444

National Crime Victimization Survey (NCVS) 2002, 399, 400, 410

National Elder Abuse Incidence Study (NEAIS), 280, 282, 429

National Health and Nutrition and Examination Survey (NHANESI), 677–678, 769–770

National Health Care Quality Report, 264

National Heart Lung and Blood Institute, obesity guidelines of, 735

National Institutes of Health, obesity guidelines of, 735

National Policy Summit on Elder Abuse, 453–454

Native American community, protection of elders by, 363

Natural Death Act (1976), 194–195

Nefazodone, 481

Neglect, 281. See also *Elder abuse, and neglect*.
legal definition of, 386

Nonsteroidal anti-inflammatory drugs (NSAIDs), 473, 499–500, 501, 516, 594–595
in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis, 552–553
in rheumatic diseases, 557

Nursing home(s), and community settings, 324–325
background checks for employees of, 349–350
bariatric programs in. See *Bariatric programs, in nursing homes*.
care in obesity, 769
care provided by, 544
goals of, 544
dealing with rheumatic pain in, 543–561
dementia in, care in, 322–324
incontinence in, 781
interviews of nurses in, definitions of
elder abuse and, 335–336
mistreatment in, 288
patient neglect in, 323–324

Pioneer Network model of care and, 289
placement in, elder abuse and, 299–301
predictors of, 322
pressure ulcers in residents of, 324
residents of, as vulnerable, 322–323
characteristics of, 288
victims of sexual abuse in, 408

Nutrient deficiencies, in obesity, 779–780

Nutrient requirements, obesity management and, 727–728

Nutritional care, planning and interventions in, in bariatric programs in nursing homes, 779–780

Nutritional evaluation, in bariatric programs in nursing homes, 776–779

O

Obese older patients. See *Obesity*.

Obesity, adverse effects of, 769
and aging population, 760–761
and functional decline, 677–687
and overweight, incidence of, 735
as epidemic in United States, 747–749
assessment of, 690
and management in, 690
attaining “ideal” body weight and, 695–696
behavioral therapy in, 720
burden of, 684
cardiovascular risk factors in, 693
clinician management of, educational materials for, 698
definition of, 759, 776
dietary management in, 697
functional limitations in, self-reported, 677–680
health risks associated with, 748
homebound status in, 680
impact on function, 684
in elderly, 713–714
and mortality, 714, 726
body composition and function in, 682
dietary management of, 725–733
health consequences of, 726
promotion of patient safety and
prevention of caregiver injury in, 759–767
intervention studies in, 682–684
laboratory evaluation in, 693–694
medical assessment in, 689–699
medical history taking in, 691
modification of home environment in, 764

morbid, definition of, 776
 health care facilities policy changes
 for, 765–766
motivation for weight loss in, 691
nursing home care in, 769
osteoarthritis in, 781, 784
pharmacotherapy in, 697
physical examination in, 693
physician intervention in, barriers to, 715
 in development of weight
 management program, 717
 lack of, 714–715
 to assess obesity risk, 716
 to assess readiness to change,
 716–717
 to establish appropriate
 interventions, 717–721
 to provide follow-up care, 720
prevalence of, 677, 678, 689, 760–761
prevention of, in overweight adults, 755
respiratory problems in, 781
risk factors exacerbating, 761
risk for pressure ulcers in, 762
sleep apnea and, 701
social history taking in, 691
stress incontinence in, 781
total joint arthroplasty and, 534
treatment of, 749
 age and, 694–695
 available, 697–698
 classification of, 695–696
 contraindications to, 696–697
 nutrient requirements and,
 727–728
 pharmacologic agents for, 735–746
 surgical, 697–698
versus overweight, classification of,
 747, 748

Older adults. *See Elderly.*

Opiates, 475–478

Opioid analgesics, starting doses for, 555

Opioid receptors, 100–101

Opioids, 475–478

 and opioid receptors, mechanism of
 action of, 99–101
 anticonvulsive drugs and, 104
 anti-infective agents and, 103
 benzodiazepines and, 104
 clearance of, macrolides and, 103
 drug interactions with, 102–105
 histamine H₂-antagonists and, 104
 intraspinal, 102
 metoclopramide and, 105
 monoamine oxidase inhibitors and, 105
 naturally occurring, 99
 pharmacology of, 99–102
 phenothiazines and, 105

proton pump inhibitors and, 104
rotation of, 105–106
routes of administration of, 101–102
selective serotonin reuptake inhibitors
 and, 105
semisynthetic, 99
side effects of, 106–108
St. John's Wort and, 105
synthetic, 99
tolerance of, mechanisms of, 101
tricyclic antidepressants and, 104–105

Opiophobia, 475

Orlistat, and sibutramine, efficacy trials
 comparing, 740–741
 cholesterol and, 742–743
 contraindications to use of, 738
 efficacy trials of, 739–742
 for weight reduction, 735, 737–738
 gastrointestinal effects of, 738
 mechanism of action of, 737
 patient information for use of, 744
 vitamin absorption and, 738

Osteoarthritis, 522

 biomarkers for, 594
 biomechanical factors in, 592
 chondrocyte biology and, 591
 epidemiology of, 590
 genetic contributions to, 591–592
 in obesity, 781, 784
 incidence of, 543
 joint laxity and, 592
 new developments in, 589–601
 pain in, algorithm for management of,
 548–549
 pathogenesis of, 590–593
 radiography in, 593–594
 synovial inflammation and, 592–593
 total joint arthroplasty in, 527–528
 treatment of, 594–598
 pharmacologic, 589, 594–595

Osteoblasts, 603, 606

Osteoclasts, 603, 604, 606

Osteoporosis, 603–629

 androgens and, 619
 biphosphonates and, 617–618
 bone loss in, 605
 calcitonin therapy and, 617
 calcium, vitamin D, and calcitriol
 and, 616
 clinical manifestations of, 609
 diagnosis of, 613–614
 differential diagnosis of, 608–609
 estrogen replacement and, 616–617
 fracture-related, 609
 glucocorticoids and, 641
 laboratory and radiologic features of,
 609–611

management of, 614–615
 measurements of skeletal mass and, 612–613
 pathophysiology of, 605–608
 sodium fluoride and, 618
 strontium ranelate and, 619–620

Overeaters Anonymous, 718

Overweight, and obesity, incidence of, 735
 definition of, 759, 776
 versus obesity, classification of, 747, 748

Oxycodone, 476

P

Pain, acute, 467–468
 treatment of, traditional versus modern, 469
 assessment of, and management of, in palliative care, 166
 and symptoms of, 94–96
 barriers to, in elderly, 565–567
 functional status and, 570–571
 history in, 568–570
 in agitated delirium, 96–97
 in elderly, 546–547
 physical examination in, 570
 psychologic and social, 571
 care in, areas for improvement of, 558
 chronic, 468, 471
 assessment of, 567–574
 and effective pain management, 563–564
 in rheumatic diseases, **563–576**
 definition of, 564
 classification of, 94
 consequences of, 563
 creation of comprehensive pain history in, 466
 definitions of, 564
 detection of, roadblocks to, 465
 epidemiology of, 465, 484
 etiologies of, 465
 expression of, in cancer patients, steps in, 95
 genetic component of, 100
 history taking in, 487
 in cognitively impaired, assessment of, 574
 behavioral manifestations of, 573
 in elderly, management of, 99–110
 nonpharmacologic approaches to, 110
 treatment of, 93–94
 in osteoarthritis, algorithm for management of, 548–549
 in rheumatoid arthritis, algorithm for management of, 550–551

intensity of, measurement of, and pain assessment scales, 571–574
 management of, by trained health professionals, 243–244
 medication history in, 466
 musculoskeletal, descriptors of, 472
 neuropathic, descriptors of, 472
 nonpharmacologic approaches to, 547–548
 Numeric Rating Scale and, 546, 547
 patient-related behaviors in, 466, 485–486
 perception of, in elderly, 545–546
 treatment, and management of, in elderly, **465–490**
 persistent, common misconceptions on, 466, 486
 consequences of, 469
 development of, 465, 484
 management of, 484
 recognition of, 466, 486
 setting health care professional barriers in, 466, 486–497
 pharmacologic options in, 549–558
 pharmacotherapeutic plan in, 470
 psychosocial and somatic aspects of, 468
 relief of, hastening death, acceptance of, 182
 rheumatic, assessment of, 545
 dealing with, in extended care facilities, **543–561**
 incidence of, 543
 increasing with increasing age, 544
 unrecognized and untreated, 543–544
 signs and symptoms of, 466, 485
 treatment guidelines for, of American Medical Directors Association, 544–545
 Verbal Descriptor Scale and, 546

Pain and Palliation Research Group, St. Olavs University Hospital, 89–90

Pain assessment instruments, 572

Pain assessment scales, measurement of intensity of pain and, 571–574

Pain interview, sample questions in, 569

Palliative care, African Americans and, case illustrating, 248–250
 as public health issue, 46–51
 assessment instruments in. See *Assessment instruments*.
 barriers to capacity and assent to, 247
 changes in population and, 46, 47
 communication skills, ethics, and law in, 166, 169–170

cost-benefit studies of, family medical costs and benefits and, 159 family nonmedical costs and benefits and, 159–160 patient medical benefits and, 157–158 patient medical costs and, 156–157 patient nonmedical benefits and, 158–159

cost-effective solutions to, 51–52 costs and benefits of, classification of, 149, 150 measurement of, 151–156 description/definition of, 20–22 disadvantaged groups and, 50–51 economic deprivation and, 48–49 education and research in, 79–80 education in, 165–175 educational assessment in, 168–169 educational resources for, 172 effects of, on patient medical costs, 150–151 elderly and, 49 ethical, legal, and policy issues in, 177–178 ethnic and minority groups and, 49–50 evidence-based medicine in, 261 experiential education and faculty development in, 171–172 foundational concepts for, 27 geriatric medicine and, 57–65 challenges and lessons in, 12–14 clinical practice of, 9–10 comparison between, 8 conceptual framework of, 4 education in, 11–12 historical comparisons of, 7–8 history of, 4 in developing countries, 58–59 acceptability of, 71 access issues in, 72–73 accessibility and, 69–70 action groups for, 74 affordability and, 70–71 availability and, 69 drug availability and, 75 economic factors and, 59, 60 elders as caregivers in, 66–67 elders as patients in, 67–69 ethical issues and, 71–72 guidance for starting programs in, 62–65 health of elderly and, 60–61 HIV/AIDS and, 65, 66 policy issues in, 73–74 public health aspects of, 60–61 setting up services for, 62, 64 statistics on, 65–66 status of elderly and health, 61–62 knowledge and research in, 8–9

guiding principles of, 29 health care interventions and, 149–150 health systems and, 167, 171 in developing countries, for elderly, diverse modes of, 72 for young people, 72 international aspects of, in elderly, 57–78 learning formats in, 168 learning objectives in, 168 models, standards, and guidelines for, 17–44 needs assessment in, 167–168 negotiation of patient goals in, 170 nonpain symptom assessment and management in, 166 organizational model for, steps to develop value of, 24–33 value of, 24, 28 organizations providing, challenges for, 23–24 pain and symptom education in, 169 pain assessment and management in, 166 price of, 147–163 psychosocial care in, 167, 170 public health and, 45–55 research in, agenda of, 85–86 building up of, 81–92 collaboration of groups for, 86–87 ethical challenges and, 84 funding for, 87–88 in Norway, external evaluation of, 90 interdisciplinary, 88 justification for, 84–87 leadership for, 87 obstacles to, 83–84 promotion of, 82 quest for, 83 resources concerning, 34, 40 service delivery models of, 22–23 synthetic approach to, Africans Americans and, 245–246 unmet need and suffering and, 46–48 WHO definition of, 70

Palliative care programs, 77–78

Palliative Care Research Initiative, of Canadian Institute of Health Care Research, 83

Palliative medicine/hospice/end-of-life care, timelines in, 6–7

Palliative sedation, 234–235

Parathyroid hormone, bone cell function and, 604, 618–619

Patient(s), costs and benefits of palliative care to, cost-benefit studies of, 156–159 measurement of, 151–153

family of, and health care team, medical decision-making and, 220
 costs and benefits of palliative care to, 159–160
 medical costs to, effects of palliative care on, 150–151
 nonmedical costs and benefits of, 153–154
 wants/goals of, medical decision-making and, 215–217

Patient Self-Determination Act (PSDA), 195

Pentazocine, 478–479

Pharmacodynamics, in elderly, 652

Pharmacokinetics, and pharmacologic activity, 471
 in elderly, 652

Pharmacotherapy, and older adults, 743–744
 for treatment of obesity, 735–746
 in obesity, 697
 in sleep apnea, 706

Phenothiazines, opioids and, 105

Phentermine, adverse effects of, 736
 and other drugs, effects of, 736
 efficacy trials of, 738
 for treatment of obesity, 736

Physical abuse, 280
 legal definition of, 385–386

Physical activity, and exercise, in bariatric programs in nursing homes, 782–783
 role in weight management and functional improvement, 747–757
 current level of, and exercise recommendations, 691
 daily, role of, 753–754
 for weight change, 730
 moderate-intensity, examples of, 754
 specialized equipment for facilitate, 751

Physical examination, in obesity, 693

Physical performance testing, in elevated body mass index, 680–681

Physical restraints, in Alzheimer's disease, 317

Physician(s), action of, death and, 211–212
 definitions of futility and, 213–215
 duties of, at end of life, 186
 reporting of elder abuse by, 294
 suspicion of motives of, 212

Physician-assisted suicide. See *Suicide, physician-assisted*.

Physician-assisted weight loss and maintenance, in elderly, 713–723

POLST form, 195

Polyangiitis, microscopic, 636–637

Polyarteritis nodosa, 633–634

Polymyalgia rheumatica, 550, 633

Polysomnography, in sleep apnea, 705–706

Powers of Attorney documents, checking on, 376–377

Pressure ulcers, as sign of neglect, 344–345
 causes of, 762
 in obesity, 762, 775–776
 in residents of nursing homes, 324
 staging of, 762

Project on Death in America (PDIA), 82

Proposed Elder Justice Act of 2003, 388

Propoxyphene, 477–478
 in rheumatic pain, 558

Protein liquids, and calorie restriction, for weight loss, 730

Protein requirements, calculation of, in obesity, 778–779
 in elderly, 727

Proton pump inhibitors, opioids and, 104

Proxy decisions, advance directives and, 197–198

Proxy interests, advance directives and, 198

Pseudogout, 491, 502–506, 520–521

Public health, traditional, roots of, 45–46

Pulmonary function, weight loss and, 729

Q

Quality-adjusted life years (QALY), 149
 and Health Utilities Index, 151–152
 benefits of palliative care for family and, 155
 to measure patient medical costs and benefits, 151–153

Quality of life. See *Elder abuse, quality of life*.

Quill, Timothy E., 179

R

Raloxifene, 617

Rape, prevalence estimates of, 400–401

Research Network of European Association for Palliative Care (EAPC), 82

Respiratory events, sleep-disordered, definitions associated with, 702, 703

Respiratory problems, in obesity, 781

Rheumatic diseases, disorders included in, 543
in elderly, assessing chronic pain in, 563–576
dealing with rheumatic pain in, 543–561
rheumatoid arthritis, 513–525

Rheumatic disorders, drug-related adverse events masquerading as, 577

Rheumatic pain. See *Pain, rheumatic*.

Rheumatic syndromes, iatrogenic, in elderly, 577–588

Rheumatoid arthritis, 513–525
clinical presentations of, 514
diagnosis of, 513–514, 515
differential diagnosis of, 516, 520–522
disease-modifying antirheumatic drugs in, 649–669
elderly onset, 514, 515
etiology and pathogenesis of, 514–515
morbidity and mortality associated with, 649
pain in, algorithm for management of, 550–551
prognosis in, 515–516
therapy of, 516–520

S

Saunders, Cicely, 69, 83

Scleroderma, drug-induced, 586

Sedation, palliative, 234–235

Selective serotonin reuptake inhibitors, opioids and, 105

Self-neglect, 281, 282–283
legal definition of, 386
risk factors for, 283

Senior Citizens Against Marketing Scams Act (SCAMS), 396

Sexual abuse, 280
background of, 414–415
case study of, 418–419
criminal justice process and outcomes in, 406–407
of elderly, core data elements tracking, 413–427
incidence of, 414
study in, 415–416
conceptual framework of, 416–419
crime and case disposition core elements, 424–425
offender core elements and, 423–424
victim care elements and, 419–423
of elderly females, forensic markers in, 399–412
of older adults, studies of, 401–402
compared, 409–410
methods of, 402–403
results of, 403–406
offender in, characteristics of, 423
and patterns of behavior in, 405–406
prosecution of cases of, forensic markers and, 407–408
under-reporting of, 399
victims of, forensic examination of, 405
in community-based care, 408
in nursing homes, 408
mechanisms of injury to, 403–404
patterns of injury to, 404, 405

Sexual assault, signs of, 343

Sexual Assault Nurse Examiner (SANE), 402, 410, 416

Sibutramine, adverse effects of, 737
and orlistat, efficacy trials comparing, 740–741
contraindications to, 737
efficacy trials of, 738–739
for weight loss, 735, 736–737
MAOIs and, 737
metabolites of, 736

Skeletal mass, measurements of, osteoporosis and, 612–613

Skeletal muscle relaxants, 482–483

Skin care, in bariatric programs in nursing homes, 775
in urinary incontinence, 763

Skin injury, immobility-related, 761–762

Sleep, in elderly, 707–708

Sleep apnea, and coronary artery disease, mortality in, 708–709
gastroesophageal reflux and, 709–710
in elderly, 701–712
obesity and, 701
obstructive, and cardiovascular diseases, 708–709
clinical presentation of, 704
cognitive function and, 710
diagnosis of, 705–706
hypertension and, 708
physical examination findings in, 704–705
prevalence of, 701–702
polysomnography in, 705–706

surgery in, 706–707
 symptoms of, 704
 treatment of, 706–707

Sleep architecture, changes in, in aging, 707

Sleep-disordered breathing, 702
 events during, 703

Sleep-disordered respiratory events, definitions associated with, 702, 703

Sleep Heart Health study, 708

Sleep history, in obesity, 692–693

Sleep-promoting agents, 483

Social isolation, as sign of neglect, 345

Social Security number, protection of, 376, 377

Sodium fluoride, osteoporosis and, 618

St. Christopher's Hospice, 83

St. John's Wort, opioids and, 105

Statins, myopathic syndromes related to, 578
 management of, 580–581
 pathogenesis of, 579–580
 risk factors associated with, 578–579

pharmacology of, 579
 prescription of, recommendations for, 581

Strengthening or resistance exercises, 752

Stress, and psychologic decline, quality of life and, 297–298

Stress incontinence, in obesity, 780–781

Strontium ranelate, osteoporosis and, 619–620

Suicide, physician-assisted, 179–192
 and euthanasia, 233–234
 arguments against, 185–187
 arguments in favor of, 183–185
 as means of expressing autonomy, 244
 concerns of patients requesting, 187
 debate concerning, 179
 definition of, 181
 legal changes and, 179–180
 steps to reduce perceived need for, 187

Sulfasalazine, efficacy of, 657–658
 history of, 655–656
 mechanism of action of, 656–657
 structure of, 656
 toxicity of, 657

Surrogate decision making, standard of evidence for, 231

Synovial inflammation, osteoarthritis and, 592–593

Systemic lupus erythematosus, 582

T

Take Off Pounds Sensibly (TOPS), 719

Telemarketing fraud, 395

“Terminal sedation,” 182–183, 184

Tight skin syndromes, drug-induced, 586

Tizanidine, 483

Topiramate, 482

Tracheostomy, in sleep apnea, 706

Tramadol, 474–475

Transfer equipment, for bariatric unit, 772

Treatment, futile. See *Futile treatment*. withdrawal of, 212

Trial of Non-pharmacologic Interventions in Elderly (TONE), 682–683

Tricyclic antidepressants, 480–481

U

United States Congress House Select Committee of Aging, 384–385

United States Panel on Cost-Effectiveness, guidelines of, 148–149

Uric acid, serum, drugs increasing, 584

Urinary incontinence, skin care in, 763

Uvulopalatopharyngoplasty, in sleep apnea, 706

V

Values, and thoughts, changes in, in brain injury or disease, 193–194

Vasculitis(ides), cryoglobulinemic, 639
 cytotoxic therapies in, 642
 drug-induced, 586
 glucocorticoids in, 641
 in geriatric population, 631–647
 in patients over age 65, 631–639
 infection and, 640–641
 isolated cutaneous, 637–638
 large vessel, 632–633
 management considerations in, 639–643
 medication interactions in, 642–643
 medium vessel, 633

primary, 631–638
secondary, 638–639
small vessel, 634–638

Venlafaxine, 480–481

Victim advocacy organizations, 441–442

Visual analog scale (VAS), in pain assessment, 97

Vitamin B₁₂, for older adults, 728

Vitamin D, for older adults, 728
osteoporosis and, 616

Vitamins, absorption of, orlistat and, 738

W

Waist circumference, measurement of, in prediction of mortality, 776–777

Walking, and dietary restriction, for weight loss, 730

Wegener's granulomatosis, 635–636

Weight-bearing exercise, 752

Weight control, exercise in, 749

Weight gain, as common in older adults, 748
causes of, 726

Weight loss, and maintenance, physician-assisted, in elderly, 713–723
barriers to success of, 720–721
depression and, 721
dietary restriction and walking for, 730

in elderly, considerations for, 726–727
options for, 729–730

in treatment of sleep apnea, 706

motivation for, in obesity, 691

protein liquids and calorie restriction for, 730

recommendations for, 744

social support for, 720–721

sustained reinforcement for, 720

Weight-loss drugs, in elderly, trials of, 744

Weight-loss program(s), as big business, 730
commercial, 718–720
energy expenditure in, 753–754
exercise in, 718, 731
healthy diet for, 717–718
“lifestyle activity” in, 753
monitoring in, 696
recommendations for, 731

Weight loss treatment, patient readiness for, evaluation of, 691

Weight management program, development of, physician intervention in, 717

Weight reduction, intervention studies in, 682–684
strategies for, 728–729

Weight Watchers, 719

Women's shelters, 444

World Health Organization (WHO), Aging and Health program of, 65
definition of palliative care, 70

Wound care, in obesity, 776